Please use this identifier to cite or link to this item:
On the Drug Pricing System
of Health Insurance System in Taiwan
Drug Expenditure Target,Drug Price Difference,Three-in-One System,Drug price adjustment,
|Publication Year :||2018|
|Abstract:||本文以訪談調查的方式訪問6位醫藥界的專家學者，探討藥品費用分配比率目標制度(DET)上路後對藥價的影響，以及探討DET執行前後對新藥引進的影響，以及未來的藥價政策可能的改革方向。藥品費用分配比率目標制(DET)隨著二代健保上路後，原想藉由 DET 之設定能預估藥價刪減對相關產業的衝擊，卻因醫療資源投入明顯不足以及執行釋法有偏差之下，雖然每年調整藥價但藥費占全部醫療費用的比例卻下降有限，從2014年的26.44%至2016年的25.93%，僅僅微幅下降0.51%，而醫藥界對其也有頗多意見。本研究綜合專訪專家學者分析後，結論與建議如下：
This study interviews six experts and scholars to explore the impact of the Drug Expenditure Target (DET) on the price of drugs, and that of the introduction of new drugs before and after the implementation of DET, and the future drug pricing policy. DET with the second Generation NHI on the road, was originally intended to estimate the impact of drug price balance cuts on relevant industries through the setting of DET. However, it was deferred due to the obvious shortage of medical resources and the implementation of interpretation. In the following, although the annual adjustment of drug prices, the proportion of drug costs in the total medical expenses has decreased by a narrow margin, from 26.44% in 2014 to 25.93% in 2016, only a slight drop of 0.51%.
After comprehensive analysis of this study by experts and scholars, the conclusions and recommendations are as follows:
1. Most experts and scholars do not agree with the establishment of the Annual DET by the The National Health Insurance administration. When the market exceeds the DET, adjustments based on current market survey data suggest that other factors should be added for more extensive discussion. In addition, it is also considered that the implementation of DET is quite limited for the narrowing of drug price balance differences.
2. The study shows that experts and scholars believe that the impact of DET on the introduction of new drugs is limited. Most think that the drug price spread has become increasingly stable in recent years, and most hospitals still use the first and second types of drugs, and the pharmaceutical companies are still evaluating the benefits. Drugs with niche points will be introduced.
3. Most experts and scholars disagree with the implementation of the three-in-one drug system, which can solve the current problem of drug price difference. The main problems lie in the current bargaining system and the hospital's feedback system.
4. In terms of future reforms, experts and scholars recommend that reference can be made to Canada's personal health fund account, or that due to the aging of the population due to demographic ageing, consideration should be given to the reasons for the growth of drug costs. The value of the base period should be reduced by the actual amount used in the previous year, and reduce the duplication and waste of medicines/medical examinations from various systems.
|Appears in Collections:||事業經營碩士在職學位學程|
Files in This Item:
|3 MB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.